EMA accepts Thrombogenics' MAA for ocriplasmin for retinal disease
This article was originally published in Scrip
The European Medicines Agency (EMA) has accepted for review Thrombogenics' marketing authorisation application (MAA) for ocriplasmin (2.5 mg/ml, solution for injection) for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole. Ocriplasmin's MAA will be evaluated through the EMA's centralised procedure with an official start date of 19 October 2011 and, if approved, the product will gain marketing authorisation for all EU Member States simultaneously. Successful approval will make it the first pharmacological treatment for this indication.